Form 4: Intensity Therapeutics Director Thomas Dubin Acquires Stock Options
SEC Form 4 Filing
Director Thomas Dubin acquired 50,000 stock options in Intensity Therapeutics, Inc. on May 14, 2024.
Summary
- On May 14, 2024, Thomas I H Dubin, a director of Intensity Therapeutics, Inc., acquired 50,000 stock options.
- The options have an exercise price of $4.42.
- The options vest in four equal annual installments starting on May 14, 2024, subject to continued service.
- The options expire on May 14, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be seen as a positive signal, this is just an option grant, not an open market purchase.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, transact in their company's stock. This provides transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of the transaction: Thomas Dubin acquired 50,000 stock options. |
| 05/14/2024 | Vesting start date: Options vest in four equal annual installments beginning on this date. |
| 05/14/2034 | Expiration date of the stock options. |
| 05/15/2024 | Date of signature by Attorney-in-fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.